Connecticut is currently home to 1218 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Novel Approaches to the Treatment of Hypothyroidism
NCT06731764
Recruiting
Hypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine. There is an unmet need to define a safe, effective, and feasible regimen to be applied in large trials aimed at assessing levothyroxine/liothyronine combination therapy in patients living with hypothyroidism. To address this knowledge gap we propose a randomized, three-arm, double-blind, controlled, esca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: UConn Health, Farmington, Connecticut
Conditions: Hypothyroidism
Register for Updates
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
NCT06671977
Recruiting
The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects. We expect that DMT will induce changes in neuroplasticity as indexed using electroencephalographic (EEG) measures and tasks in both depressed individuals and healthy volunteers, though to differe... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
03/25/2025
Locations: Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West Haven, Connecticut
Conditions: Major Depression Disorder, Depression
Register for Updates
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197
Recruiting
This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/25/2025
Locations: Research Site, Hamden, Connecticut
Conditions: Moderate to Severe Crohn's Disease
Register for Updates
A Phase 2 Study to Evaluate DNTH103 in Adults with Generalized Myasthenia Gravis (MAGIC)
NCT06282159
Recruiting
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/25/2025
Locations: Clinical Study Site, Stamford, Connecticut
Conditions: Myasthenia Gravis, Generalized
Register for Updates
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951
Recruiting
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab. These types of study drugs are collectively known as immune checkpoint inhibitors. The study is focused on participants with a type of skin cancer known as melanoma. The objective of this study is to see if... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Melanoma
Register for Updates
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this ext... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2025
Locations: Neumora Investigator Site, Norwalk, Connecticut
Conditions: Major Depressive Disorder
Register for Updates
Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
NCT05957159
Recruiting
The primary objective of this multimodal positron emission tomography (PET) study is to use PET brain imaging to measure both MOR (Mu-Opioid receptors) and KOR (kappa-opioid receptors) in participants with alcohol use disorder (AUD) and to quantify the relationships between MOR and KOR, separately and jointly, to key clinical outcomes (e.g., craving, mood, withdrawal, time to lapse) during a quit attempt.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
03/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Alcohol Use Disorder
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/25/2025
Locations: Research Site, New Haven, Connecticut
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Empagliflozin in Patients With Cirrhosis and Ascites
NCT05726032
Recruiting
A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Cirrhosis, Liver Failure
Register for Updates
Brain-Training Treatment for Long COVID in Older Adults
NCT05705193
Recruiting
This research is being done to collect preliminary data on the potential of computerized "brain-training" exercises for treating Long COVID symptoms in older adults. The investigators hypothesize that computerized brain-training will be an acceptable and feasible intervention for treating Long COVID symptoms in older adults. The investigators also expect to provide initial evidence that computerized brain-training has potential for improving thinking, mood, and other aspects of everyday function... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/25/2025
Locations: UConn Health, Farmington, Connecticut
Conditions: Post-Acute COVID-19 Syndrome
Register for Updates
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT05629208
Recruiting
The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/25/2025
Locations: Yale Center for Clinical Investigation (YCCI), New Haven, Connecticut
Conditions: Cutaneous Lupus Erythematosus (CLE)
Register for Updates